Follow us on:

Linkedin Facebook

Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

Haleon delivers 3.4% organic revenue growth in Q3 2025 driven by oral health and VMS

Haleon reported Q3 2025 revenue of £2.8 billion, reflecting 3.4% organic growth, led by strong performances in Oral Health and Vitamins, Minerals and Supplements...

One Health Group Strong Growth, Strategic Hubs, and Confidence in the Future (Video)

One Health Group’s Chairman Derek Bickerstaff outlines another period of strong growth — with patient referrals, surgeons, and capacity all sharply higher...
GSK Plc

GSK Plc lifts 2025 guidance after strong Q3 sales and profit growth

GSK reported Q3 2025 sales of £8.5 billion, up 8% at constant exchange rates, driven by strong performances across Specialty Medicines, Vaccines and General Medicines...
GSK

GSK receives EMA Orphan Drug Designation for GSK5764227 in Pulmonary NEC

GSK has announced that its B7-H3-targeted antibody-drug conjugate, GSK5764227 (GSK'227), has been granted Orphan Drug Designation by the European Medicines Agency for treating pulmonary neuroendocrine carcinoma, including small-cell lung cancer...
Nuformix plc

Nuformix launches £228,000 underwritten Open Offer at 0.2p per share

Nuformix has announced an underwritten Open Offer to raise approximately £228,081 through the issue of 114,040,535 shares at 0.2p each...
One Health Group

One Health Group reports 17% revenue growth and strong H1 performance

One Health Group reported a 17% rise in revenue to £15.5 million for the six months to 30 September 2025, supported by double-digit increases across all key metrics...
GSK

GSK Plc gains FDA approval for Blenrep combination in multiple myeloma

GSK has received FDA approval for Blenrep (belantamab mafodotin-blmf) with bortezomib and dexamethasone to treat adults with relapsed or refractory multiple myeloma after at least two prior therapies...
Physicians Capital

Industry insider joins Physicians Capital advisory team

Earl Anderson joins Physicians Capital as Strategic Advisor, bringing 40+ years of leadership in orthopaedics to support physician ownership and investment growth...
Syncona Limited

Syncona outlines £250m shareholder return plan and refined investment strategy

Syncona has announced a new set of proposals focused on returning £250 million to shareholders through future portfolio realisations and refining its investment strategy to maximise long-term value...
AstraZeneca

AstraZeneca Tezspire approved in the US for chronic rhinosinusitis with nasal polyps

The US FDA has approved AstraZeneca and Amgen’s Tezspire (tezepelumab) as an add-on maintenance treatment for patients aged 12 and over with inadequately controlled chronic rhinosinusitis with nasal polyps...
EDX Medical Group plc

EDX Medical secures up to £4m to accelerate diagnostic product development

EDX Medical has raised up to £4 million to advance its digital diagnostic products for cancer, cardiovascular, and infectious diseases. The funding includes a £2 million share placing at 14p per share and a £2 million convertible loan note from founder Professor Sir Chris Evans...
Physicians Capital

Medical offices redefine the next phase of property investment

Medical office buildings are emerging as one of the most dependable investment classes in commercial real estate, combining steady demand, long leases, and structural demographic support...
Physicians Capital

Understanding what really drives medical property value

In medical property investment, valuation is about understanding how risk, lease structure, and investor conviction converge to define true worth...
Aptamer Group

Aptamer Group delivers 40% revenue growth and expands licensing portfolio

Aptamer Group has announced its full-year results for the twelve months ended 30 June 2025, delivering a 40% increase in revenue to £1.2 million and expanding its Optimer® licensing portfolio from four to eleven assets...
Aptamer

Aptamer Group secures repeat contract for Optimer® binder development

Aptamer Group has signed a new agreement with an existing partner to develop Optimer® binders targeting two proteins for biomarker research...
AstraZeneca

AstraZeneca Plc reaches agreement with Trump administration to cut US drug prices

AstraZeneca has signed a landmark agreement with President Donald J. Trump’s administration to reduce the cost of prescription medicines for American patients...
Nuformix plc

Nuformix appoints Kreston Reeves Audit as new auditor

Nuformix has appointed Kreston Reeves Audit LLP as its new auditor following the restructuring of Kreston Reeves LLP...
Aptamer

Aptamer Group to announce full year 2025 results on 14 October

Aptamer Group will publish results for the year ended 30 June 2025 on Tuesday, 14 October 2025, with an online analyst briefing at 9.30 am hosted by CEO Dr Arron Tolley and CFO Andrew Rapson. ...
Smith & Nephew plc

Smith & Nephew to host Capital Markets Days in London and New York

Smith & Nephew will hold Capital Markets Days on 8 December in London and 11 December in New York to outline its new strategy, mid-term priorities, and portfolio growth plans...
Aptamer Group

Aptamer Group secures £360,000 contract with top 3 global pharma

Aptamer Group has signed a £360,000 development contract with a leading global pharmaceutical company to engineer Optimer® binders as targeted radiopharmaceuticals...
Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest Interviews

BrokerTalk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

Haleon delivers 3.4% organic revenue growth in Q3 2025 driven by oral health and VMS

Haleon reported Q3 2025 revenue of £2.8 billion, reflecting 3.4% organic growth, led by strong performances in Oral Health and Vitamins, Minerals and Supplements...

One Health Group Strong Growth, Strategic Hubs, and Confidence in the Future (Video)

One Health Group’s Chairman Derek Bickerstaff outlines another period of strong growth — with patient referrals, surgeons, and capacity all sharply higher...
GSK Plc

GSK Plc lifts 2025 guidance after strong Q3 sales and profit growth

GSK reported Q3 2025 sales of £8.5 billion, up 8% at constant exchange rates, driven by strong performances across Specialty Medicines, Vaccines and General Medicines...
GSK

GSK receives EMA Orphan Drug Designation for GSK5764227 in Pulmonary NEC

GSK has announced that its B7-H3-targeted antibody-drug conjugate, GSK5764227 (GSK'227), has been granted Orphan Drug Designation by the European Medicines Agency for treating pulmonary neuroendocrine carcinoma, including small-cell lung cancer...
Nuformix plc

Nuformix launches £228,000 underwritten Open Offer at 0.2p per share

Nuformix has announced an underwritten Open Offer to raise approximately £228,081 through the issue of 114,040,535 shares at 0.2p each...
One Health Group

One Health Group reports 17% revenue growth and strong H1 performance

One Health Group reported a 17% rise in revenue to £15.5 million for the six months to 30 September 2025, supported by double-digit increases across all key metrics...
GSK

GSK Plc gains FDA approval for Blenrep combination in multiple myeloma

GSK has received FDA approval for Blenrep (belantamab mafodotin-blmf) with bortezomib and dexamethasone to treat adults with relapsed or refractory multiple myeloma after at least two prior therapies...
Physicians Capital

Industry insider joins Physicians Capital advisory team

Earl Anderson joins Physicians Capital as Strategic Advisor, bringing 40+ years of leadership in orthopaedics to support physician ownership and investment growth...
Syncona Limited

Syncona outlines £250m shareholder return plan and refined investment strategy

Syncona has announced a new set of proposals focused on returning £250 million to shareholders through future portfolio realisations and refining its investment strategy to maximise long-term value...
AstraZeneca

AstraZeneca Tezspire approved in the US for chronic rhinosinusitis with nasal polyps

The US FDA has approved AstraZeneca and Amgen’s Tezspire (tezepelumab) as an add-on maintenance treatment for patients aged 12 and over with inadequately controlled chronic rhinosinusitis with nasal polyps...
EDX Medical Group plc

EDX Medical secures up to £4m to accelerate diagnostic product development

EDX Medical has raised up to £4 million to advance its digital diagnostic products for cancer, cardiovascular, and infectious diseases. The funding includes a £2 million share placing at 14p per share and a £2 million convertible loan note from founder Professor Sir Chris Evans...
Physicians Capital

Medical offices redefine the next phase of property investment

Medical office buildings are emerging as one of the most dependable investment classes in commercial real estate, combining steady demand, long leases, and structural demographic support...
Physicians Capital

Understanding what really drives medical property value

In medical property investment, valuation is about understanding how risk, lease structure, and investor conviction converge to define true worth...
Aptamer Group

Aptamer Group delivers 40% revenue growth and expands licensing portfolio

Aptamer Group has announced its full-year results for the twelve months ended 30 June 2025, delivering a 40% increase in revenue to £1.2 million and expanding its Optimer® licensing portfolio from four to eleven assets...
Aptamer

Aptamer Group secures repeat contract for Optimer® binder development

Aptamer Group has signed a new agreement with an existing partner to develop Optimer® binders targeting two proteins for biomarker research...
AstraZeneca

AstraZeneca Plc reaches agreement with Trump administration to cut US drug prices

AstraZeneca has signed a landmark agreement with President Donald J. Trump’s administration to reduce the cost of prescription medicines for American patients...
Nuformix plc

Nuformix appoints Kreston Reeves Audit as new auditor

Nuformix has appointed Kreston Reeves Audit LLP as its new auditor following the restructuring of Kreston Reeves LLP...
Aptamer

Aptamer Group to announce full year 2025 results on 14 October

Aptamer Group will publish results for the year ended 30 June 2025 on Tuesday, 14 October 2025, with an online analyst briefing at 9.30 am hosted by CEO Dr Arron Tolley and CFO Andrew Rapson. ...
Smith & Nephew plc

Smith & Nephew to host Capital Markets Days in London and New York

Smith & Nephew will hold Capital Markets Days on 8 December in London and 11 December in New York to outline its new strategy, mid-term priorities, and portfolio growth plans...
Aptamer Group

Aptamer Group secures £360,000 contract with top 3 global pharma

Aptamer Group has signed a £360,000 development contract with a leading global pharmaceutical company to engineer Optimer® binders as targeted radiopharmaceuticals...
Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest interviews

Broker Talk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

Latest Interviews

FTSE 100 News

FTSE 250 News

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

BrokerTalk

FTSE 100

Funds

View all Funds, Market Insights and news >> 

Green News

View all Sustainable sectors, Plcs and news >>  

UK Broker Ratings

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple